Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin: Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity

Giorgio Minotti, Cesare Mancuso, Andrea Frustaci, Alvaro Mordente, Stefano A. Santini, Antonio Maria Calafiore, Giovanni Liberi, Nicolo' Gentiloni

Research output: Contribution to journalArticle

Abstract

Anticancer therapy with doxorubicin (DOX) and other quinone anthracyclines is limited by severe cardiotoxicity, reportedly because semiquinone metabolites delocalize Fe(II) from ferritin and generate hydrogen peroxide, thereby promoting hydroxyl radical formation and lipid peroxidation. Cardioprotective interventions with antioxidants or chelators have nevertheless produced conflicting results. To investigate the role and mechanism(s) of cardiac lipid peroxidation in a clinical setting, we measured lipid conjugated dienes (CD) and hydroperoxides in blood plasma samples from the coronary sinus and femoral artery of nine cancer patients undergoing intravenous treatments with DOX. Before treatment, CD were unexpectedly higher in coronary sinus than in femoral artery (342±131 vs 112±44 nmol/ml, mean±SD; P <0.01), showing that cardiac tissues were spontaneously involved in lipid peroxidation. This was not observed in ten patients undergoing cardiac catheterization for the diagnosis of arrhythmias or valvular dysfunctions, indicating that myocardial lipid peroxidation was specifically increased by the presence of cancer. The infusion of a standard dose of 60 mg DOX/m2 rapidly (~ 5 min) abolished the difference in CD levels between coronary sinus and femoral artery (134±95 vs 112±37 nmol/ml); moreover, dose fractionation studies showed that cardiac release of CD and hydroperoxides decreased by ~ 80% in response to the infusion of as little as 13 mg DOX/m2. Thus, DOX appeared to inhibit cardiac lipid peroxidation in a rather potent manner. Corollary in vitro experiments were performed using myocardial biopsies from patients undergoing aortocoronary bypass grafting. These experiments suggested that the spontaneous exacerbation of lipid peroxidation probably involved preexisting Fe(II) complexes, which could not be sequestered adequately by cardiac isoferritins and became redox inactive when hydrogen peroxide was included to simulate DOX metabolism and hydroxyl radical formation. Collectively, these in vitro and in vivo studies provide novel evidence for a possible inhibition of cardiac lipid peroxidation in DOX-treated patients. Other processes might therefore contribute to the cardiotoxicity of DOX.

Original languageEnglish
Pages (from-to)650-661
Number of pages12
JournalJournal of Clinical Investigation
Volume98
Issue number3
Publication statusPublished - Aug 1 1996

Fingerprint

Anthracyclines
Doxorubicin
Lipid Peroxidation
Hydrogen Peroxide
Coronary Sinus
Neoplasms
Femoral Artery
Ferritins
Hydroxyl Radical
Coronary Vessels
Dose Fractionation
Cardiotoxicity
Cardiac Catheterization
Chelating Agents
Coronary Artery Bypass
Oxidation-Reduction
Cardiac Arrhythmias
Therapeutics
Antioxidants
Lipids

Keywords

  • cardiotoxicity
  • doxorubicin
  • free radicals
  • iron
  • lipid peroxidation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin : Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity. / Minotti, Giorgio; Mancuso, Cesare; Frustaci, Andrea; Mordente, Alvaro; Santini, Stefano A.; Calafiore, Antonio Maria; Liberi, Giovanni; Gentiloni, Nicolo'.

In: Journal of Clinical Investigation, Vol. 98, No. 3, 01.08.1996, p. 650-661.

Research output: Contribution to journalArticle

Minotti, Giorgio ; Mancuso, Cesare ; Frustaci, Andrea ; Mordente, Alvaro ; Santini, Stefano A. ; Calafiore, Antonio Maria ; Liberi, Giovanni ; Gentiloni, Nicolo'. / Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin : Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity. In: Journal of Clinical Investigation. 1996 ; Vol. 98, No. 3. pp. 650-661.
@article{5124c62d84c54b2ead13fae6fa635787,
title = "Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin: Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity",
abstract = "Anticancer therapy with doxorubicin (DOX) and other quinone anthracyclines is limited by severe cardiotoxicity, reportedly because semiquinone metabolites delocalize Fe(II) from ferritin and generate hydrogen peroxide, thereby promoting hydroxyl radical formation and lipid peroxidation. Cardioprotective interventions with antioxidants or chelators have nevertheless produced conflicting results. To investigate the role and mechanism(s) of cardiac lipid peroxidation in a clinical setting, we measured lipid conjugated dienes (CD) and hydroperoxides in blood plasma samples from the coronary sinus and femoral artery of nine cancer patients undergoing intravenous treatments with DOX. Before treatment, CD were unexpectedly higher in coronary sinus than in femoral artery (342±131 vs 112±44 nmol/ml, mean±SD; P <0.01), showing that cardiac tissues were spontaneously involved in lipid peroxidation. This was not observed in ten patients undergoing cardiac catheterization for the diagnosis of arrhythmias or valvular dysfunctions, indicating that myocardial lipid peroxidation was specifically increased by the presence of cancer. The infusion of a standard dose of 60 mg DOX/m2 rapidly (~ 5 min) abolished the difference in CD levels between coronary sinus and femoral artery (134±95 vs 112±37 nmol/ml); moreover, dose fractionation studies showed that cardiac release of CD and hydroperoxides decreased by ~ 80{\%} in response to the infusion of as little as 13 mg DOX/m2. Thus, DOX appeared to inhibit cardiac lipid peroxidation in a rather potent manner. Corollary in vitro experiments were performed using myocardial biopsies from patients undergoing aortocoronary bypass grafting. These experiments suggested that the spontaneous exacerbation of lipid peroxidation probably involved preexisting Fe(II) complexes, which could not be sequestered adequately by cardiac isoferritins and became redox inactive when hydrogen peroxide was included to simulate DOX metabolism and hydroxyl radical formation. Collectively, these in vitro and in vivo studies provide novel evidence for a possible inhibition of cardiac lipid peroxidation in DOX-treated patients. Other processes might therefore contribute to the cardiotoxicity of DOX.",
keywords = "cardiotoxicity, doxorubicin, free radicals, iron, lipid peroxidation",
author = "Giorgio Minotti and Cesare Mancuso and Andrea Frustaci and Alvaro Mordente and Santini, {Stefano A.} and Calafiore, {Antonio Maria} and Giovanni Liberi and Nicolo' Gentiloni",
year = "1996",
month = "8",
day = "1",
language = "English",
volume = "98",
pages = "650--661",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin

T2 - Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity

AU - Minotti, Giorgio

AU - Mancuso, Cesare

AU - Frustaci, Andrea

AU - Mordente, Alvaro

AU - Santini, Stefano A.

AU - Calafiore, Antonio Maria

AU - Liberi, Giovanni

AU - Gentiloni, Nicolo'

PY - 1996/8/1

Y1 - 1996/8/1

N2 - Anticancer therapy with doxorubicin (DOX) and other quinone anthracyclines is limited by severe cardiotoxicity, reportedly because semiquinone metabolites delocalize Fe(II) from ferritin and generate hydrogen peroxide, thereby promoting hydroxyl radical formation and lipid peroxidation. Cardioprotective interventions with antioxidants or chelators have nevertheless produced conflicting results. To investigate the role and mechanism(s) of cardiac lipid peroxidation in a clinical setting, we measured lipid conjugated dienes (CD) and hydroperoxides in blood plasma samples from the coronary sinus and femoral artery of nine cancer patients undergoing intravenous treatments with DOX. Before treatment, CD were unexpectedly higher in coronary sinus than in femoral artery (342±131 vs 112±44 nmol/ml, mean±SD; P <0.01), showing that cardiac tissues were spontaneously involved in lipid peroxidation. This was not observed in ten patients undergoing cardiac catheterization for the diagnosis of arrhythmias or valvular dysfunctions, indicating that myocardial lipid peroxidation was specifically increased by the presence of cancer. The infusion of a standard dose of 60 mg DOX/m2 rapidly (~ 5 min) abolished the difference in CD levels between coronary sinus and femoral artery (134±95 vs 112±37 nmol/ml); moreover, dose fractionation studies showed that cardiac release of CD and hydroperoxides decreased by ~ 80% in response to the infusion of as little as 13 mg DOX/m2. Thus, DOX appeared to inhibit cardiac lipid peroxidation in a rather potent manner. Corollary in vitro experiments were performed using myocardial biopsies from patients undergoing aortocoronary bypass grafting. These experiments suggested that the spontaneous exacerbation of lipid peroxidation probably involved preexisting Fe(II) complexes, which could not be sequestered adequately by cardiac isoferritins and became redox inactive when hydrogen peroxide was included to simulate DOX metabolism and hydroxyl radical formation. Collectively, these in vitro and in vivo studies provide novel evidence for a possible inhibition of cardiac lipid peroxidation in DOX-treated patients. Other processes might therefore contribute to the cardiotoxicity of DOX.

AB - Anticancer therapy with doxorubicin (DOX) and other quinone anthracyclines is limited by severe cardiotoxicity, reportedly because semiquinone metabolites delocalize Fe(II) from ferritin and generate hydrogen peroxide, thereby promoting hydroxyl radical formation and lipid peroxidation. Cardioprotective interventions with antioxidants or chelators have nevertheless produced conflicting results. To investigate the role and mechanism(s) of cardiac lipid peroxidation in a clinical setting, we measured lipid conjugated dienes (CD) and hydroperoxides in blood plasma samples from the coronary sinus and femoral artery of nine cancer patients undergoing intravenous treatments with DOX. Before treatment, CD were unexpectedly higher in coronary sinus than in femoral artery (342±131 vs 112±44 nmol/ml, mean±SD; P <0.01), showing that cardiac tissues were spontaneously involved in lipid peroxidation. This was not observed in ten patients undergoing cardiac catheterization for the diagnosis of arrhythmias or valvular dysfunctions, indicating that myocardial lipid peroxidation was specifically increased by the presence of cancer. The infusion of a standard dose of 60 mg DOX/m2 rapidly (~ 5 min) abolished the difference in CD levels between coronary sinus and femoral artery (134±95 vs 112±37 nmol/ml); moreover, dose fractionation studies showed that cardiac release of CD and hydroperoxides decreased by ~ 80% in response to the infusion of as little as 13 mg DOX/m2. Thus, DOX appeared to inhibit cardiac lipid peroxidation in a rather potent manner. Corollary in vitro experiments were performed using myocardial biopsies from patients undergoing aortocoronary bypass grafting. These experiments suggested that the spontaneous exacerbation of lipid peroxidation probably involved preexisting Fe(II) complexes, which could not be sequestered adequately by cardiac isoferritins and became redox inactive when hydrogen peroxide was included to simulate DOX metabolism and hydroxyl radical formation. Collectively, these in vitro and in vivo studies provide novel evidence for a possible inhibition of cardiac lipid peroxidation in DOX-treated patients. Other processes might therefore contribute to the cardiotoxicity of DOX.

KW - cardiotoxicity

KW - doxorubicin

KW - free radicals

KW - iron

KW - lipid peroxidation

UR - http://www.scopus.com/inward/record.url?scp=0029910238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029910238&partnerID=8YFLogxK

M3 - Article

C2 - 8698856

AN - SCOPUS:0029910238

VL - 98

SP - 650

EP - 661

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -